Compare CNTX & RNGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNTX | RNGT |
|---|---|---|
| Founded | 2015 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.9M | 313.0M |
| IPO Year | 2021 | N/A |
| Metric | CNTX | RNGT |
|---|---|---|
| Price | $2.25 | $10.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $6.60 | N/A |
| AVG Volume (30 Days) | ★ 747.3K | 19.0K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.49 | $9.90 |
| 52 Week High | $3.62 | $10.05 |
| Indicator | CNTX | RNGT |
|---|---|---|
| Relative Strength Index (RSI) | 41.64 | 61.75 |
| Support Level | $2.07 | $9.95 |
| Resistance Level | $2.58 | N/A |
| Average True Range (ATR) | 0.19 | 0.01 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 12.10 | 83.33 |
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Range Capital Acquisition Corp II is a blank check company.